MBX (MBX Biosciences) Cash-to-Debt : 1,319.35 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is MBX Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MBX Biosciences's cash to debt ratio for the quarter that ended in Sep. 2024 was 1,319.35.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MBX Biosciences could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for MBX Biosciences's Cash-to-Debt or its related term are showing as below:

MBX' s Cash-to-Debt Range Over the Past 10 Years
Min: 92.11 Med: 221.94 Max: 249
Current: 221.94

During the past 2 years, MBX Biosciences's highest Cash to Debt Ratio was 249.00. The lowest was 92.11. And the median was 221.94.

MBX's Cash-to-Debt is ranked better than
83.05% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs MBX: 221.94

MBX Biosciences Cash-to-Debt Historical Data

The historical data trend for MBX Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MBX Biosciences Cash-to-Debt Chart

MBX Biosciences Annual Data

Trend

Dec22

Dec23

Cash-to-Debt

92.11

249.00

MBX Biosciences Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial			N/A	N/A	249.00	221.94	1,319.35

Competitive Comparison of MBX Biosciences's Cash-to-Debt

For the Biotechnology subindustry, MBX Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's Cash-to-Debt falls into.

MBX Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

MBX Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	80.676	/	(0.153	+	0.171)
	=	249.00

MBX Biosciences's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	277.063	/	(0.166	+	0.044)
	=	1,319.35

MBX Biosciences (NAS:MBX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

MBX Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of MBX Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MBX Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MBX Biosciences Inc (NAS:MBX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032

Website

https://www.mbxbio.com

MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.